Aulos Bioscience is an immuno-oncology company working to revolutionize cancer patient care through immune-activating antibody therapeutics that direct patients’ immune systems toward killing tumor cells. The company’s lead asset, imneskibart (AU-007), is in a Phase 1/2 clinical study, with interim Phase 2 data demonstrating clear evidence of deep and durable tumor shrinkages, including complete and partial responses, in patients whose tumors were refractory to treatment and had achieved no responses from highly potent prior immuno-oncology regimens. Data also show durable reductions in immunosuppressive Treg cells – a compelling result in the IL-2 class – and correlated progression-free survival.
If you’re interested in investing in Aulos, please contact info@aulosbio.com.
AULOS CO-FOUNDERS
Aulos was co-founded by Biolojic Design and ATP, with $60 million in Series A funding from ATP. The company is led by pioneers in the fields of artificial intelligence, antibody development and cancer immunotherapies.
LATEST NEWS
AULOS FEATURED IN THE NEWS
Empowered Patient Podcast
Harnessing AI to Design Antibodies and Further Unlock the Immune System to Target Cancer Cells with Aron Knickerbocker Aulos Bioscience
August 6, 2025
Host Karen Jagoda and CEO Aron Knickerbocker dive into why Aulos is a company to watch and its “moon landing” with an AI-assisted antibody that drives down Tregs – a first in the IL-2 class.
BiotechTV
SITC 2024: Aulos Bioscience CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company’s IL-2 redirecting antibody
November 9, 2024
CEO Aron Knickerbocker and BiotechTV’s Brad Loncar review AU-007 safety and efficacy data presented at SITC, including a correlation between Treg reduction and longer progression-free survival.
VIDEOS ABOUT OUR TECHNOLOGY
Understanding the human immune system and combating diseases like cancer can be complex. In the fight against cancer, what if artificial intelligence could design a drug that helps solve one of the biggest challenges in immunotherapy – safely harnessing the power of IL-2?
The currently approved form of recombinant human IL-2 requires high doses that can be toxic and lead to cytokine storms as well as increased risk of pulmonary edema and blood vessel leakage. Newer generation IL-2 mimetics that are not yet approved can also create a negative feedback loop by triggering the secretion of more IL-2, which can lead to the expansion of regulatory T cells that suppress the very immune response the cancer treatment was meant to activate. Addressing these complexities requires IL-2 regulation, precision and innovation. That’s where Aulos comes in.